PN summer web series kicks off in July! Learn more

DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Drug Status

In October 2011, the FDA designated KRN5500 – a drug being developed to treat chronic chemotherapy-induced PN (CCIPN) – with ‘Fast Track’ status. Today DARA BioSciences applied for orphan drug status for KRN5500. Orphan drug status is provided to products that treat rare conditions for which there are few adequate therapies. No approved treatments currently exist for CCIPN. READ MORE

Source: BusinessWire